Hospitalizations for Inflammatory Bowel Disease Among Medicare Fee-for-Service Beneficiaries — United States, 1999–2017

Fang Xu,Anne G. Wheaton,Yong Liu,Hua Lu,Kurt J. Greenlund

DOI: https://doi.org/10.15585/mmwr.mm6849a2

2019-12-13

Abstract:From 1999 to 2017, hospitalization rates for inflammatory bowel disease decreased among non-Hispanic white Medicare beneficiaries but not among non-Hispanic black Medicare beneficiaries.

What problem does this paper attempt to address?

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study

Michael J Buie,Stephanie Coward,Abdel-Aziz Shaheen,Jayna Holroyd-Leduc,Lindsay Hracs,Christopher Ma,Remo Panaccione,Eric I Benchimol,Charles N Bernstein,Alain Bitton,Anthony R Otley,Jennifer L Jones,Sanjay K Murthy,M Ellen Kuenzig,Juan-Nicolás Peña-Sánchez,Laura E Targownik,Harminder Singh,Antonio Avina-Zubieta,Gilaad G Kaplan

DOI: https://doi.org/10.1093/ibd/izad020

2023-10-03

Abstract:Background: Recent advances in the management of inflammatory bowel disease (IBD) striving for new treatment targets may have decreased rates of hospitalization for flares. We compared all-cause, IBD-related, and non-IBD-related hospitalizations while accounting for the rising prevalence of IBD. Methods: Population-based, administrative health care databases identified all individuals living with IBD in Alberta between fiscal year 2002 and 2018. Hospitalization rates (all-cause, IBD-related, and non-IBD-related) were calculated using the prevalent Alberta IBD population. Hospitalizations were stratified by disease type, age, sex, and metropolitan status. Data were age and sex standardized to the 2019 Canadian population. Log-linear models calculated Average Annual Percentage Change (AAPC) in hospitalization rates with associated 95% confidence intervals (CIs). Results: From 2002-2003 to 2018-2019, all-cause hospitalization rates decreased from 36.57 to 16.72 per 100 IBD patients (AAPC, -4.18%; 95% CI, -4.69 to -3.66). Inflammatory bowel disease-related hospitalization rate decreased from 26.44 to 9.24 per 100 IBD patients (AAPC, -5.54%; 95% CI, -6.19 to -4.88). Non-IBD-related hospitalization rate decreased from 10.13 to 7.48 per 100 IBD patients (AAPC, -1.82%; 95% CI, -2.14 to -1.49). Those over 80 years old had the greatest all-cause and non-IBD-related hospitalization rates. Temporal trends showing decreasing hospitalization rates were observed across age, sex, IBD type, and metropolitan status. Conclusions: Hospitalization rates are decreasing for all-cause, IBD-related, and non-IBD-related hospitalizations. Over the past 20 years, the care of IBD has transitioned from hospital-based care to ambulatory-centric IBD management.
Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States

Fang Xu,Yong Liu,Anne G. Wheaton,Kristina M. Rabarison,Janet B. Croft

DOI: https://doi.org/10.1007/s40258-018-0432-4

2018-09-27

Applied Health Economics and Health Policy

Abstract:Abstract Background Few studies have addressed recent trends in hospitalization costs for inflammatory bowel disease (IBD). Objective We explored trends and described patient and hospital factors associated with hospitalization costs for IBD. Methods Using data from the 2003–2014 National Inpatient Sample for adults aged ≥ 18 years, we estimated costs using multivariable linear models and assessed linear trends by time periods using piecewise linear regressions. Results In 2014, there were an estimated 56,290 hospitalizations for Crohn’s disease (CD), with a mean cost of US$11,345 and median cost of US$7592; and 33,585 hospitalizations for ulcerative colitis (UC), with a mean cost of US$13,412 and median cost of US$8873. Higher costs were observed among Hispanic [adjusted cost ratio (ACR) = 1.07; 95% confidence interval (CI) = 1.00–1.14; p = 0.04] or other non-Hispanic (ACR = 1.09; 95% CI = 1.02–1.17; p = 0.01) CD patients than for non-Hispanic White CD patients. For UC patients, higher costs were observed among men (ACR = 1.09; 95% CI = 1.05–1.13; p < 0.001) compared with women and among patients aged 35–44 years, 45–54 years, and 55–64 years compared with those aged 18–24 years. Among all patients, factors associated with higher costs included higher household income, more comorbidities, and hospitals that were government nonfederal versus private, were large versus small, and were located in the West versus Northeast regions. From 2003 to 2008, total costs increased annually by 3% for CD (1.03; 95% CI = 1.02–1.05; p < 0.001) and 4% for UC (1.04; 95% CI = 1.02–1.06; p < 0.001), but remained unchanged from 2008 to 2014. Conclusions The findings are important to identify IBD patients with higher hospitalization costs and to inform policy plans on hospital resource allocation.

health care sciences & services,health policy & services,economics
Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

Lingya Yao,Haotian Chen,Bule Shao,Jing Liu,Chaohui Wang,Zhou Zhang,Qian Cao

DOI: https://doi.org/10.1093/ibd/izab327

2022-01-01

Inflammatory Bowel Diseases

Abstract:Background The temporal trends in medical treatment and long-term outcomes of patients with Crohn's disease (CD) have not been well elucidated in China over the past 2 decades. Accordingly, we aimed to evaluate the treatment paradigm and long-term clinical course of Chinese patients with CD in a hospital-based cohort. Methods All adult patients newly diagnosed with CD (n = 1338) between 1999 and 2019 in the Sir Run Run Shaw Hospital were included in this cohort. Medication utilization, disease outcomes, and risk factors were investigated. Results Overall, 48.7%, 35.6%, 67.8%, and 61.6% of patients used 5-aminosalicylates (5-ASA), corticosteroids, thiopurines, and infliximab (IFX), respectively. The cumulative risk of 5-ASA and corticosteroid initiation decreased during follow-up, whereas that of IFX initiation increased. Throughout a median follow-up duration of 26.4 (interquartile range, 12.0-49.2) months, a total of 486 and 300 patients underwent hospitalization and surgery, respectively. Of the 1097 patients with B1/B2 disease behavior at diagnosis, 10.3% experienced phenotype progression. The hospitalization rate decreased after 2015; however, surgery and phenotype progression rates did not significantly change. A Cox regression analysis indicated that IFX use since diagnosis was a contributing factor for lower rates of hospitalization and phenotype progression, whereas thiopurine use was associated with a lower surgery rate. Conclusions Infliximab use was observed to increase as 5-ASA and corticosteroid use decreased. Additionally, hospitalization rates decreased following temporal changes in IFX management, yet the surgery and phenotype progression rates remained the same.
Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses

Michael J. Buie,Joseph W. Windsor,Stephanie Coward,Tawnya M. Hansen,James A. King,Paulo G. Kotze,Richard B. Gearry,Siew C. Ng,Maria T. Abreu,David T. Rubin,Charles N. Bernstein,Rupa Banerjee,Jesus K. Yamamoto-Furusho,Remo Panaccione,Cynthia H. Seow,Christopher Ma,Fox E. Underwood,Vineet Ahuja,Nicola Panaccione,Abdel-Aziz Shaheen,Jayna Holroyd-Leduc,Gilaad G. Kaplan,Domingo Balderramo,Vui Heng Chong,Fabián Juliao-Baños,Usha Dutta,Marcellus Simadibrata,Jamilya Kaibullayeva,Yang Sun,Ida Hilmi,Raja Affendi Raja Ali,Mukesh Sharma Paudel,Mansour Altuwaijri,Juanda Leo Hartono,Shu Chen Wei,Julajak Limsrivilai,Sara El Ouali,Beatriz Iade Vergara,Viet Hang Dao,Paul Kelly,Phoebe Hodges,Yinglei Miao,Maojuan Li,Joshua Quan,Joyce W.Y. Mak

DOI: https://doi.org/10.1016/j.cgh.2022.06.030

IF: 13.576

2022-07-01

Clinical Gastroenterology and Hepatology

Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn's disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change (AAPC) with associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data were stratified by the epidemiologic stage of a region: compounding prevalence (stage 3) in North America, Western Europe, and Oceania vs acceleration of incidence (stage 2) in Asia, Eastern Europe, and Latin America vs emergence (stage 1) in developing countries.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">Hospitalization rates for a primary diagnosis of IBD were stable in countries in stage 3 (AAPC, -0.13%; 95% CI, -0.72 to 0.97), CD (AAPC, 0.20%; 95% CI, -1.78 to 2.17), and UC (AAPC, 0.02%; 95% CI, -0.91 to 0.94). In contrast, hospitalization rates for a primary diagnosis were increasing in countries in stage 2 for IBD (AAPC, 4.44%; 95% CI, 2.75 to 6.14), CD (AAPC, 8.34%; 95% CI, 4.38 to 12.29), and UC (AAPC, 3.90; 95% CI, 1.29 to 6.52). No population-based studies were available for developing regions in stage 1 (emergence).</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hospitalization rates for IBD are stabilizing in countries in stage 3, whereas newly industrialized countries in stage 2 have rapidly increasing hospitalization rates, contributing to an increasing burden on global health care systems.</AbstractText>

gastroenterology & hepatology
P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

L Yao,B Shao,Q Cao

DOI: https://doi.org/10.1093/ecco-jcc/jjab232.606

2022-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The temporal changes in medication use and therapeutic paradigm in patients with Inflammatory bowel disease (IBD) have not been well elucidated in China over the past two decades. Therefore, we aimed to identify the temporal changes in medication use and treatment patterns for Chinese patients with IBD and to evaluate the factors associated with initial drug strategies. Methods A multicenter retrospective cohort study was conducted among Chinese patients newly diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) from January 1999 to December 2019. Medication utilization, treatment patterns, and associated factors with initial drug strategies were investigated. Results Prescriptions of 5-aminosalicylates (ASA) and corticosteroids (CS) gradually decreased, whereas prescriptions of immunosuppressants (IMS) and infliximab (IFX) increased in patients with CD. Except for stable prescriptions of ASA and CS, IMS and IFX increased since 2007 in patients with UC. Subgroup (N=957) analyses revealed that treatment patterns went through notable changes from ASA to IMS or IFX in patients with CD, while ASA and CS were still steadily prescribed in patients with UC. Logistic regression analyses revealed that perianal and gastrointestinal surgeries before diagnosis, disease behavior, and disease location were associated with different initial therapeutic strategies in patients with CD. However, medications before diagnosis, disease location, and diagnostic year might affect initial strategies in patients with UC. Conclusion Parallel to increasing uses of IMS and IFX in IBD over past two decades, a significant decrease in uses of ASA and CS were observed in CD, but not in UC. Treatment strategies analyses provided a unique insight in understanding long-term therapeutic patterns in the Chinese population.
A31 GLOBAL BURDEN OF HOSPITALIZATION FOR PERSONS WITH IBD IN THE 21ST CENTURY: TIME TREND ANALYSES

J W Windsor,M Buie,S Coward,J A King,F Underwood,J Quan,R Panaccione,C Seow,G G Kaplan

DOI: https://doi.org/10.1093/jcag/gwz006.030

2019-03-01

Journal of the Canadian Association of Gastroenterology

Abstract:Prevalence of inflammatory bowel disease (IBD) exceeds 0.3% in N. America, Europe, and Oceania, but many Westernized nations report decreasing hospitalization rates (HR) following the advent of biologics. However, IBD incidence is rapidly rising in newly industrialized countries in Asia and S. America, which may correspond to increasing HRs in those regions. Analyze global time trends of all-cause hospitalizations for persons with IBD. We conducted a systematic review of MedLine and Embase (2000–2018) to identify population-based studies reporting HRs after the year 2000 with at least five years of data. WorldBank census data were used for population values. Log-linear models were used to analyze time trends and to calculate average annual percentage change (AAPC), with associated 95% confidence intervals (CI). 7,782 studies were identified; 663 underwent full-text review; data were extracted from 52; and, 17 underwent analysis. HRs were analyzed in 33 countries (Table 1). In N. America, HRs are decreasing in Canada (AAPC:−2.4; 95%CI:−2.6,−2), but increasing in the USA (AAPC:2.4; 95%CI:1.5,3.3). HRs were also divergent in Europe with countries reporting decreasing (eg. Sweden, AAPC:−2.4; 95%CI:−2.9,−1.8), increasing (eg. Germany, AAPC:2.1; 95%CI:1.8,2.5), and stable (eg. France, AAPC:−0.1; 95%CI:−0.4,0.2) rates. In contrast, HRs were rapidly increasing in Asia (eg. China, AAPC:16.4; 95%CI:11.8,21.2) and S. America (eg. Mexico, AAPC:3.7; 95%CI:2.8,4.6) (Table 1). Despite advances in IBD management since 2000, HRs are divergent throughout the Western world with over half of countries reporting increases. Newly industrialized countries in Asia and S. America are experiencing rapidly rising HRs, which is contributing to an increasing burden on global healthcare systems. Table 1: Hospital discharge rates by country since 2000 with average annual percent change (AAPC) and 95% confidence intervals (CI). *p < 0.05 CIHR
Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020

Saleha Aziz,Anum Akhlaq,Anna Owings,Sana Gurz,Yousaf Zafar,Basim Ali,Shou-Jiang Tang

DOI: https://doi.org/10.1093/ibd/izae184

2024-09-11

Abstract:Background: The prevalence and disease course of inflammatory bowel disease (IBD) have evolved over the years. It is unknown how these factors have impacted all-cause mortality. Our study assesses IBD mortality trends in the United States over 20 years by age, sex, and race. Methods: We used the Centers for Disease Control Wide-Ranging OnLine Data for Epidemiologic Research database for multiple causes of death in Crohn's disease (CD) and ulcerative colitis (UC) from 1999 to 2020. Age-adjusted mortality rates (AAMR) and crude mortality rates per 100 000 population were obtained. Joinpoint Analysis Software was used for annual percentage change (APC) overall and by age, sex, and race (White and Black). Results: Overall AAMR in CD and UC were 0.79 and 0.53, respectively. All-cause mortality was stable from 1999 to 2018. There was a significant rise in APC from 2018 to 2020 (CD vs. UC, +11.28 vs. +9.29). This rise was observed across both races, sexes, and ages ≥45 years in the last 2-4 years of the study. AAMR in females compared with males varied in CD (0.81 vs. 0.79) and UC (0.45 vs. 0.62). White adults had higher AAMR than Black adults in both CD (0.94 vs. 0.50) and UC (0.58 vs. 0.28). The crude mortality rate increased with age and was highest in those ≥85 years (CD vs. UC, 5.07 vs. 5.23). Conclusions: All-cause mortality trends in IBD were stable until 2018 and rose between 2018 and 2020. Mortality rates were higher amongst the elderly and White adults. Females with CD and males with UC had higher mortality rates.
Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database

Edward L Barnes,Renee M Beery,Allison R Schulman,Ellen P McCarthy,Joshua R Korzenik,Rachel W Winter,Edward L. Barnes,Renee M. Beery,Allison R. Schulman,Ellen P. McCarthy,Joshua R. Korzenik,Rachel W. Winter

DOI: https://doi.org/10.1097/mib.0000000000000899

2016-09-01

Inflammatory Bowel Diseases

Abstract:BACKGROUND: Questions remain regarding the true prevalence of cardiovascular events such as myocardial infarction (MI) among patients with inflammatory bowel disease (IBD). Using the Nationwide Inpatient Sample (NIS), we aimed to compare the proportion of hospitalizations for acute MI among patients with IBD with that of the general population.METHODS: This study used data from years 2000 to 2011 in Nationwide Inpatient Sample, the largest publicly available all-payer inpatient database in the United States. International Classification of Diseases, Ninth Revision, Clinical Modification discharge codes were used to identify adult patients with discharge diagnoses of IBD (ulcerative colitis or Crohn's disease), acute MI, and multiple comorbid risk factors for cardiovascular disease. The independent effect of a diagnosis of IBD on risk of acute MI was examined using a multivariable logistic regression model controlling for multiple confounders. Data were analyzed using SAS survey procedures and weighted to reflect national estimates.RESULTS: We identified 567,438 hospitalizations among patients with IBD and 78,121,000 hospitalizations among the general population. Patients with IBD were less likely to be hospitalized for acute MI than patients in the general population (1.3% versus 3.1%, P < 0.001). In adjusted analyses, the odds of hospitalization for acute MI among patients with IBD were decreased when compared with the general population (odds ratio, 0.51; 95% confidence interval, 0.50-0.52).CONCLUSIONS: Despite prior reports of a potentially increased risk of acute MI among patients with IBD, in a nationwide inpatient database, lower rates of acute MI were demonstrated in the IBD population when compared with the general population.

gastroenterology & hepatology
P1138 Long-term Epidemiological Trends in Emergency Hospital Admissions and Hospitalizations of Patients with Inflammatory Bowel Diseases in one of the biggest metropolises in western Poland in years 2010 to 2021

D Mahadea,P Kotecki,I Miechowicz,A Dobrowolska,P Eder

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1268

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background A worldwide significant dynamic shift in the incidence and clinical course of Inflammatory Bowel Diseases (IBD) has been observed in the past years. One key indicator that embodies this variability is the necessity for urgent hospitalisation due to exacerbations of Crohn's Disease (CD) and Ulcerative Colitis (UC). The objective of this study was to assess this phenomenon in the Poznan Metropolis, one of the biggest metropolises in western Poland, over a 12-year timeframe. Methods Using the National Health Fund's database, urgent hospitalisations of patients with CD or UC from 2010-2021 were identified, and defined as unplanned admissions to emergency departments and inpatient units in Poznan Metropolis hospitals, which required hospitalisation. The ratio of emergency to planned hospitalisations were compared in two identical timeframes: 2010-2015 vs. 2016-2021 and, additionally, during the COVID-19 pandemic years 2020-2021 vs. 2018-2019. The data were analysed and compared according to diagnosis, age, gender and length of hospitalisation. Results The numbers of urgent and planned hospitalisations in regard to predefined time periods are shown in Table 1. The rate of acute to planned hospitalisations from 2010-2015 vs. 2016-2021 was 27% (809/3006) vs. 44.5% (1131/2540) (p <0.0001). It increased significantly in all defined categories, except for patients over 60 years of age, where an insignificant decrease from 79% to 71% (p=0.4) was noted. Lower hospitalisation rates were observed among men compared to women (2010-2015: 28% vs. 46%; 2016-2021: 25% vs. 43%). The COVID-19 pandemic posed a paramount challenge to global healthcare systems. However, a statistically significant decrease in the rate of urgent to planned hospitalisations was only found in CD patients (47% vs. 34%; p=0.02; Figure 1). No impact on hospitalisation duration was observed during the COVID-19 pandemic as compared to 2018-2019. Conclusion Despite ongoing therapeutic advances, IBD remains a substantial challenge to healthcare systems, as evidenced by the increasing trend in urgent hospitalisations over time, regardless of the diagnosis, particularly among women. The COVID-19 pandemic significantly triggered global economic and healthcare crisis. However, the repercussions on the treatment of IBD patients in our Metropolis were inconsequential.

gastroenterology & hepatology
Mucosal Healing Among Black and White Patients With Inflammatory Bowel Disease

Devika Dixit,Nicole C Ruiz,Steve Shen,Arvin Daneshmand,Vanessa I Rodriguez,Steve Qian,Dan Neal,S Devi Rampertab,Ellen M Zimmermann,Amir Y Kamel

DOI: https://doi.org/10.14309/ctg.0000000000000737

2024-08-01

Abstract:Introduction: Crohn's disease and ulcerative colitis are characterized by chronic inflammation of the gastrointestinal tract. Mucosal healing (MH) is a therapeutic goal in patients with inflammatory bowel disease (IBD). Current data suggest that Black patients may experience worse clinical outcomes than White patients with IBD. This study assessed MH between Black and White patients with IBD. Methods: Retrospective analysis was performed on Black and White adults with IBD who were hospitalized for an active flare. The presence of MH was assessed at 6-18 months after hospitalization. IBD treatments received before and during hospitalization, within 6 months, and 6-18 months after discharge were recorded. C-reactive protein (CRP) levels were collected at hospitalization and 6-18 months after discharge; the difference was reported as delta CRP. Results: One hundred nine patients were followed up after hospitalization. Of those 88 (80.7%) were White patients, and 21 (19.3%) were Black patients. White and Black patients received similar proportions of IBD treatment before ( P = 0.2) and during ( P = 0.6) hospitalization, within 6 months ( P = 0.1), and 6-18 months ( P = 0.1) after discharge. Black patients achieved numerically higher rates of MH (15/21 = 71.4% vs 53/88 = 60.2%, P = 0.3) and delta CRP ( P = 0.2) than White patients, however, not statistically significant. Discussion: In patients admitted to the hospital with an IBD flare with similar treatment and care, there was a trend toward higher rates of MH in Black patients compared with White patients. These data suggest that MH is likely not the only factor that is associated with Black patients experiencing worse clinical outcomes when compared with White patients.
The national burden of inflammatory bowel disease in the United States from 1990-2019: results from the Global Burden of Disease study database

Saqr Alsakarneh,Kamal Hassan,Fouad Jaber,Micheal Mintz,Mir Zulqarnian,Ayah Obeid,Hassan Ghoz,Jana G Hashash,Francis A Farraye

DOI: https://doi.org/10.20524/aog.2024.0894

Abstract:Background: Inflammatory bowel disease (IBD) epidemiology has changed rapidly in recent years. We aimed to provide a systematic report of the burden of IBD at a state level in the United States (US), and to study the age- and sex-specific trends of incidence, prevalence and mortality rates for the past 3 decades. Methods: Using the Global Burden of Disease (GBD) 2019 Study Database, we examined the incidence, prevalence and mortality rate, and the disability-adjusted life-years from GBD 2019 at national and state level from 1990-2019. Results: There was an overall decrease in incidence and prevalence rates of IBD in the US from 1990-2019, while a simultaneous increase in the overall mortality rates was identified. However, a distinct trend of increasing incidence and prevalence rates emerged starting in 2000, with incidence rates rising from 21 cases per 100,000 persons in 2000 to 23 cases per 100,000 persons in 2019. From 1990-2019, incidence and prevalence decreased in males at a higher rate than in females. However, mortality rates increased more in females than males. Incidence rates were highest in Midwestern and Eastern states, and were lowest across the northern Great Plains and Western states, with the highest incidence noted in Michigan (31 cases per 100,000 persons). California had the greatest decrease in incidence rates from 1990-2019 (-63.3%). Conclusion: Our results concerning recent trends and geographic variations in IBD offer policymakers crucial insights for informed decision-making in policy, research, and investment, facilitating more effective strategies and allocation of resources.
S991 Increasing Mortality of Inflammatory Bowel Disease in Women: A Population-Based Time-Trend Analysis Using the Global Burden of Diseases Database, 1990-2019

J. Hashash,Laith Al momani,Hassan M. Ghoz,Kamal Hassan,S. Alsakarneh,Michael Mintz,F A Farraye,Mir A. Zulqarnain

DOI: https://doi.org/10.14309/01.ajg.0000953604.89476.76

2023-10-01

Abstract:Introduction: Patients with In ﬂ ammatory Bowel Disease (IBD) are at increased risk of death compared to the general population. However, limited data exist regarding changes in mortality rates with the introduction of biological medications in the US. The aim of this study was to conduct a time-trend analysis of age and gender-speci ﬁ c IBD mortality rates in the US using the Global Burden Diseases (GBD) 2019 database. Methods: Data was obtained from the GBD 2019 database, an international database covering most IBD diagnosed cases in the US. IBD incidence rates, age-adjusted to the standard US population, were calculated using SEER*Stat software (v.8.4.0.1, National Cancer Institute “ NCI ” ) and were strati ﬁ ed by gender, as reported in the database. Time-trends were estimated as annual percentage change (APC) and averageAPC(AAPC)usingJoinpointRegressionSoftware

Medicine
RISING INCIDENCE, MORTALITY, AND DISABILITY-ADJUSTED LIFE YEARS OF INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: A SYSTEMIC ANALYSIS OF THE GLOBAL BURDEN OF DISEASE STUDY

Chun-Wei Pan,Bashar Attar,Alejandro Nieto-Dominguez

DOI: https://doi.org/10.1093/ibd/izae020.081

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract INTRODUCTION: In North America, Inflammatory Bowel Disease (IBD) poses a significant burden, yet detailed data on its incidence, mortality, and disability-adjusted life years (DALYs) within the United States is scarce. Our study aims to systematically analyze these aspects of IBD while considering gender, age, and state-level variations. Methods: Utilizing the Global Burden of Disease database, we systematically analyzed IBD incidence, mortality, and DALYs in the United States from 1999 to 2019. We further stratified these metrics by gender and age groups (25-49 years, 50-75 years, and 75+ years) and calculated annual percentage changes (APC) using linear regression. Results: Between 1999 and 2019, IBD incidence cases increased from 65,555 to 85,388. The incidence rate per 100,000 person-years rose from 23.5 (95% UI: 21.4-26.2) to 26.0 (95% UI: 23.8-28.9), with APC of 1.0. Females consistently had higher incidence rates, increasing from 34,236 (95% UI: 31,052-38,351) in 1999 to 43,882 (95% UI: 39,953-48,871) in 2019. Incidence rates also rose, with males at 0.6% APC and females at 0.4%. In 2019, the 24-49 years age group had the highest incidence rate at 35.1 (95% UI: 30.3-40.1) per 100,000, with a 0.5% APC increase from 1999 to 2019.Mortality increased, with 5,910 IBD-related deaths in 2019. The mortality rate per 100,000 population rose from 1.1 (95% UI: 1.0-1.3) to 1.8 (95% UI: 1.4-2.0), reflecting a 2.4% APC. Although females had a higher mortality rate in 2019 (2.2 per 100,000), males had a 2.7% APC increase from 1999 to 2019. Geographically, notable differences in APC for incidence rates across states were observed. The highest increases were seen in Ohio (1.06%), North Dakota (1.04%), and Maine (0.96%), while Nevada had a slight decrease in APC (-0.02%). Mortality rate changes also varied by state, with substantial increases in Alaska (3.75%), Vermont (3.19%), and Tennessee (3.13%). Regarding DALYs, significant APC rate changes were observed in New Mexico (1.53%), Vermont (1.38%), and Mississippi (1.37%), while the lowest changes were seen in the District of Columbia (0.24%). Conclusions: This comprehensive analysis of IBD in the US from 1999 to 2019 reveals trends and disparities. IBD incidence steadily increased during this period, with notable rises in cases and rates. Gender-wise, females had higher incidence rates, while males displayed a slightly steeper increase. Geographic disparities were evident, with varying trends in incidence and mortality rates across states. Ohio, North Dakota, and Maine had the highest incidence increases, while Alaska, Vermont, and Tennessee saw significant mortality rate increases. Our study highlights the changing epidemiology of IBD and the need for targeted intervention to address changes in incidence and disease burden. Fig 1. * Denotes P

gastroenterology & hepatology
In Patients With Inflammatory Bowel Disease, Racial Disparities Exist in Burden of Vaccine-preventable Disease Hospitalizations and Outcomes

Christian Karime,Miguel Salazar,Cecily N. Black,Freddy Caldera,Philip N. Okafor,Muhammad B. Hammami,Jana G. Hashash,Francis A. Farraye

DOI: https://doi.org/10.1097/mcg.0000000000002005

2024-04-16

Journal of Clinical Gastroenterology

Abstract:Objective: Patients with inflammatory bowel disease (IBD) are at increased risk of vaccine-preventable diseases (VPDs). Despite the increasing prevalence of IBD in non-white populations, little is known regarding racial disparities in VPD burden. Methods: Retrospectively analyzing the 2016 to 2020 National Inpatient Sample, we identified adults with IBD hospitalized for a principal diagnosis of VPD. The primary outcome investigated was hospitalization for VPD stratified by patient-reported race. Secondary outcomes were in-hospital morbidity, mortality, length of stay, and health care utilization. Multivariable regression analysis was performed to adjust for patient and hospital characteristics. Results: The search identified 554,114 hospitalizations for VPD, including 4170 hospitalizations in patients with IBD. Patients with IBD had significantly greater odds of hospitalization from herpes zoster virus (adjusted odds ratio [aOR]: 1.73) and varicella zoster virus (aOR: 2.31). Comparing white and non-white patients with IBD, significant racial disparities were noted. Non-white patients were at greater odds of hospitalization from influenza (aOR: 1.74), herpes zoster virus (aOR: 1.77), and varicella zoster virus (aOR: 1.62). In-hospital morbidity was greater in non-white patients, including greater odds of requiring intensive care unit stay (aOR: 1.18). Morbidity was elevated in African Americans, with greater odds of acute kidney injury (aOR: 1.25), venous thromboembolism (aOR: 1.17), respiratory failure (aOR: 1.16), and intensive care unit stay (aOR: 1.18). No differences were found in mortality, length of stay, and health care utilization. Conclusions: Significant racial disparities in VPD hospitalization and in-hospital morbidity were found among adults with IBD in the United States. With the increasing prevalence of IBD in non-white populations, targeted efforts are needed to improve health equity.

gastroenterology & hepatology
5-Aminosalicylic Acid and Statin Use Are Associated with Reduced Risk of Cancers in Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

Jacqueline So,Whitney Tang,Francis K. Chan,Wai K. Leung,Michael K. Li,Chi Man Leung,Wai-Cheung Lao,Carmen Ka Man Ng,Fu H. Lo,Shun Fung,Alex Sze,Yee Tak Hui,Steve Tsang,Edwin H. S. Shan,Ching K. Loo,Kam H. Chan,Aric J. Hui,Wai Hung Chow,Justin C. Wu,Joseph J. Sung,Siew C. Ng

DOI: https://doi.org/10.1016/s0016-5085(17)31494-4

IF: 29.4

2017-01-01

Gastroenterology

Abstract:disease with higher rates of anemia, low BMI and non-elective surgery during hospitalization.Suboptimal healthcare access among blacks, as suggested by higher rates of Medicaid and self-payor status, was noted as well.Multivariable 30-day readmission analysis supports the fact that racial disparity could be at least partially explained by inequality in access to healthcare between blacks and whites.More studies are needed to further clarify this observation.Table 1 -Predictors of total and 30-day readmissions -Multivariate analysis Table 2-Medication use, procedures and complications during hospitalization * denotes statistically significant Sa1859
DECIPHERING THE BURDEN OF INFLAMMATORY BOWEL DISEASE LANDSCAPE (1990-2019) IN HIGH INCOME NORTH AMERICA: PROJECTIONS, TEMPORAL SHIFTS, AND A GLIMPSE BEYOND TO 2040

Rahul Patel,Vivek Roy,Sashank Sai Bollu,Sai Nitya Tejaswi Anne,Pranathi Royal Naradasu,Sneh Patel,Hardik Dineshbhai Desai

DOI: https://doi.org/10.1093/ibd/izae020.067

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND In High-Income North America, IBD ranks as the 6th leading cause of disability and the 9th primary cause of mortality among all digestive diseases. The increasing prevalence in this region underscores the urgent need to address both the clinical and socio-economic challenges of managing this chronic condition in a developed setting. METHOD Utilizing Global Burden of DIsease tool, we estimated IBD prevalence, incidence, mortality, and Disability Adjusted Life Years (DALYs) of IBD in High-Income North America. Standardized statistical techniques facilitated comparisons by age, sex, year within this specific region. The DisMod-MR 2.1 tool was employed to estimate incidence and prevalence, while mortality rates were discerned using the Cause of Death Ensemble Model (CODEm). Additionally, we projected the deaths and Years of Life Lost (YLLs) up to 2040 using regression analysis. RESULTS From 1990 to 2019, the overall IBD prevalence in High-Income North America showed a decline from 1,100,006 (95%UI: 961,427-1,248,969) to 920,749 (859,032-982,587). However, deaths rose sharply from 2,442 (2,189-2,963) in 1990 to 6,313 (5,075-6,885) in 2019, marking an Annual Percentage Change (APC) surge of 159% (84-182). Meanwhile, DALYs grew by 17% (2-33). Age-Standardized Rates (ASR) indicate a reduction in incidence and DALYs rates by 30% and 22%, respectively, while mortality rates climbed by 42% (1-54). Country-specific trends show Canada and Greenland with incidence APC increases of 28% and 37%, respectively, while the U.S. saw a 12% decline. For mortality, the U.S. led with a 172% APC rise, followed by Greenland at 1,485% and Canada at 49%. In age-specific trends, children under five witnessed a 20% APC surge in incidence per 100,000 population, whereas the under-20 age bracket saw a 13% rise. Notably, those aged under 70 experienced an 89% jump in deaths from 1990-2019. CONCLUSION The marked shift in IBD prevalence and mortality in High-Income North America over three decades underscores the escalating challenge this disease presents to the healthcare landscape. The substantial increase in deaths, especially in countries like the U.S. and Greenland, combined with the age-specific trends, emphasizes the pressing need for targeted interventions and robust healthcare policies. Notably, in 2019, IBD was responsible for 4.43% of all deaths linked to digestive diseases and contributed to 6.13% of the total disabilities arising from digestive conditions. This data accentuates the profound and growing impact of IBD in the region and demands immediate, evidence-based action.

gastroenterology & hepatology
Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases

Nghia H Nguyen,Lucila Ohno-Machado,William J Sandborn,Siddharth Singh

DOI: https://doi.org/10.1016/j.cgh.2018.07.004

Abstract:Background & aims: Approximately 15%-40% patients with inflammatory bowel diseases (IBD) are obese. There is an inconsistent association between obesity and IBD phenotype and course. We conducted a nationally representative cohort study to estimate and compare the burden, costs, and causes for hospitalization in obese vs non-obese patients with IBD. Methods: Using the Nationwide Readmissions Database 2013, we identified obese (based on administrative claims code) and non-obese patients who had been hospitalized at least once, from January through June 2013, and followed them for re-hospitalization until December 2013. We compared annual burden (total days spent in hospital), costs, causes, and outcomes of hospitalization between obese and non-obese patients after 1:1 propensity score matching. Results: We identified 42,285 patients with IBD, of which 12.4% were obese. After propensity score matching, we included 5128 obese and 5128 non-obese IBD patients in our analysis. Compared to non-obese patients, obese patients spent more days in hospital annually (median, 8 vs 5 days) (P < .01), with higher hospitalization-related costs (median, $17,277 vs $11,847) (P < .01); this pattern persisted in subsets of high-need and high-cost patients. Compared to non-obese patients, obese patients were more likely to be hospitalized with preventable admissions (19% vs 15%) or cardiopulmonary complications (16% vs 12%). Conclusions: In an analysis of data on patients with IBD from the Nationwide Readmissions Database 2013, we found obesity to be independently associated with higher burden and costs of hospitalizations. Strategies should be considered to target obesity as adjunctive therapy for patients with IBD.
The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies

Siew C. Ng,Hai Yun Shi,Nima Hamidi,Fox E. Underwood,Whitney Tang,Eric I. Benchimol,Remo Panaccione,Subrata Ghosh,Justin C. Y. Wu,Francis K. L. Chan,Joseph J. Y. Sung,Gilaad G. Kaplan

DOI: https://doi.org/10.1016/s0016-5085(17)33292-4

IF: 29.4

2017-01-01

Gastroenterology

Abstract:Background Inflammatory bowel disease is a global disease in the 21st century. We aimed to assess the changing incidence and prevalence of inflammatory bowel disease around the world. Methods We searched MEDLINE and Embase up to and including Dec 31, 2016, to identify observational, population-based studies reporting the incidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later. A study was regarded as population-based if it involved all residents within a specific area and the patients were representative of that area. To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be reported separately. Studies that did not report original data and studies that reported only the incidence or prevalence of paediatric-onset inflammatory bowel disease (diagnosis at age <16 years) were excluded. We created choropleth maps for the incidence (119 studies) and prevalence (69 studies) of Crohn's disease and ulcerative colitis. We used temporal trend analyses to report changes as an annual percentage change (APC) with 95% CI. Findings We identified 147 studies that were eligible for final inclusion in the systematic review, including 119 studies of incidence and 69 studies of prevalence. The highest reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's disease 319 per 100 000 in Canada). The prevalence of inflammatory bowel disease exceeded 0.3% in North America, Oceania, and many countries in Europe. Overall, 16 (72.7%) of 22 studies on Crohn's disease and 15 (83.3%) of 18 studies on ulcerative colitis reported stable or decreasing incidence of inflammatory bowel disease in North America and Europe. Since 1990, incidence has been rising in newly industrialised countries in Africa, Asia, and South America, including Brazil (APC for Crohn's disease + 11.1% [95% CI 4.8-17 . 8] and APC for ulcerative colitis + 14.9% [10.4-19.6]) and Taiwan (APC for Crohn's disease + 4.0% [1.0-7.1] and APC for ulcerative colitis + 4.8% [1.8-8.0]). Interpretation At the turn of the 21st century, inflammatory bowel disease has become a global disease with accelerating incidence in newly industrialised countries whose societies have become more westernised. Although incidence is stabilising in western countries, burden remains high as prevalence surpasses 0.3%. These data highlight the need for research into prevention of inflammatory bowel disease and innovations in health-care systems to manage this complex and costly disease.
Trends in Diverticular Disease Hospitalizations and Racial Disparities in Outcomes Across the United States

Fidelis E Uwumiro,Tomilola Olakunde,Adeniyi Fagbenro,Ifeoluwa Fadeyibi,Victory Okpujie,Agatha O Osadolor,Joshua Emina,Grace O Odjighoro,Nonso J Obi,Efe Erhus,Kenechukwu Umenzeakor

DOI: https://doi.org/10.7759/cureus.65572

2024-07-28

Cureus

Abstract:Objective This study evaluated trends and racial disparities in hospitalization, clinical outcomes, and resource utilization for diverticular disease (DD) between 2017 and 2020. Methods We performed a retrospective analysis using the NIS database from 1 January 2017 to 31 December 2020 to study hospitalizations for DD (CCSR code: DIG013). Our primary outcomes were hospitalization rates, all-cause mortality, total charges, and length of stay. Secondary outcomes included in-hospital complications and discharge status. Outcomes were stratified by race and ethnicity (White, Black, Hispanic, Asian or Pacific Islanders and Native Americans). Data were weighted and adjusted for clustering, stratification, and other relevant factors. The normality of the continuous data distribution was confirmed using Kolmogorov-Smirnov, and descriptive statistics were used to summarize variables. Demographic characteristics were compared using χ² and Student's t-test, with significance set at P<0.05. We used stepwise multivariable logistic regression to estimate adjusted odds ratios for study outcomes by race and ethnicity, controlling for demographic and clinical factors and correcting for multicollinearity. Missing data were treated with multiple imputations, trend analyses were performed using Jonckheere-Terpstra tests, and costs were adjusted for inflation using the GDP price index. Analyses were conducted with Stata 17MP. Results A total of 1,266,539 hospitalizations for DD were included for analysis. Approximately 953,220 (75.3%) were White patients and 313,319 (24.7) did not belong to the White race. A total of 747,868 (59%) were women compared to 518,671 (41%) men. Compared to patients who were not of the White race, White patients were younger (63.5 vs. 66.8 years; p<0.001). Hospitalizations for DD increased by 1.2% from 323,764 to 327,770 hospitalizations (2017-2019) and decreased by 11.8% from 327,770 to 289,245 admissions in 2020. Mortality rates were higher among White patients than in those not of the White race (16,205 (1.7%) vs 5,013 (1.6%)). However, no significant difference was observed in mortality odds between both sets of patients (aOR, 0.953; 95% CI 0.881-1.032; P=0.237). Mortality rates showed an uptrend over the study period (4,850 (1.5%) in 2017 to 5,630 (1.9%) in 2020; Ptrend<0.001). DD accounted for 7,016,718 hospital days, 2,102,749 procedures, and US$ 6.8 billion in hospital costs. Mean hospital costs increased from US$54,705 to US$72,564 over the study period (P<0.000). Patients who were not of the White race incurred higher mean hospital charges than White patients ($67,635 ± $6,700 vs $59,103 ± $3,850; P<0.001). Black race correlated with lower odds of bowel perforation, routine home discharge, and bowel resection (P<0.001). Conclusion During the study period, hospitalization and mortality rates and resource utilization for DD increased. Patients from other races incurred higher hospital costs than White patients. White Americans were more likely to be discharged to skilled nursing, intermediate care, and other facilities. Additionally, White patients were less likely to develop bowel abscesses compared to patients who were not White. Compared to White American patients, Black patients had fewer DD hospitalizations complicated by bowel perforations or requiring bowel resections. In contrast, DD admissions among Hispanic patients were more likely to require bowel resections than those among White American patients.
P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares

Chung Sang Tse,Sarah Andrea,Yousef Elfanagely,Joshua Tanzer,Abbas Rupawala

DOI: https://doi.org/10.14309/01.ajg.0000798820.49929.ce

2021-12-01

Abstract:Background: Adults with inflammatory bowel disease (IBD) have increased risks for gastrointestinal infections. Single-center studies in Michigan and New York report 17-31% positive enteropathogen tests in patients with symptomatic IBD. Population-based studies are lacking, particularly on factors that determine who undergo testing. Health inequities may exist in the care of patients with IBD where certain groups systematically experience social and/or economic disparities. We aim to assess sociodemographic and healthcare factors associated with enteropathogen testing of hospitalized IBD patients. Methods: In this retrospective cohort study, we identified 770 patients with IBD who had 1,189 hospital admissions for primary symptoms consistent with IBD flares/enteric infections at 3 hospitals (tertiary referral teaching, community, and county) in the largest healthcare system in Rhode Island from January 2017-March 2019. Using modified Poisson regression to estimate relative risks (RR) and 95% Confidence Intervals (CIs), we assessed enteropathogen testing status as a function of sociodemographic and clinical characteristics in separate models. Results: Patients with IBD hospitalized with symptoms consistent with IBD flares or enteric infections disproportionately had Crohn's disease (69% vs. 31% UC). Patients were 47 years old on average, 60% women, 79% non-Hispanic white, 13% Hispanic, and 7% non-Hispanic Black. Over half (55%) were privately insured, 42% publicly insured, and 2% uninsured. Over half (55%) of patients were treated with glucocorticoids within 1 week of hospitalization while 35% were on biologics. The top 5 primary symptoms for hospitalization were abdominal pain (63%), GI bleeding (8%), fever (8%), vomiting (7%), and diarrhea (7%). Enteropathogen testing (may be >1) was obtained in 46% of hospitalizations: 42% tested for C. difficile; 23 % tested for Salmonella spp., Shigella spp./enteroinvasive E. coli, Campylobacter spp., and Shiga toxin-producing organisms; and 15% had extensive testing for 22 enteropathogens (13 bacteria, 5 viruses, and 4 parasites). 10% of the tests were positive, most commonly for C. difficile (5%), E. coli spp (0.6%), Campylobacter spp (0.5%), Salmonella (0.3%), and Norovirus (0.3%). While gender differences in testing were not observed (female 45%, male 46%, F:M, RR 1.01, 95% CI 0.90,1.15), Hispanic patients were more likely to undergo enteropathogen testing than non-Hispanic white patients (58% vs 44%; RR 1.21, 95% CI 1.02-1.43). Relative to patients hospitalized at the tertiary referral teaching hospital, patients at the county hospital were 29% less likely (95% CI, 0.54-0.93) and those at the community hospital were 22% (95% CI 0.78-1.01) less likely to have enteropathogen testing. Enteropathogen testing occurred most frequently among the privately insured 48%, while uninsured were comparatively 20% less likely and publicly insured were 10% less likely to undergo testing, though neither comparison was statistically significant. Conclusion: Racial/ethnic (Hispanic vs non-Hispanic White) and healthcare settings (county vs tertiary referral teaching hospital) differences in enteropathogen testing patterns were observed in adults with IBD hospitalized primarily for GI symptoms at the state of Rhode Island's largest healthcare system. Further studies to assess health inequities, including sociodemographic and organizational differences, in the healthcare delivery in IBD are warranted.

Hospitalizations for Inflammatory Bowel Disease Among Medicare Fee-for-Service Beneficiaries — United States, 1999–2017

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study

Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

A31 GLOBAL BURDEN OF HOSPITALIZATION FOR PERSONS WITH IBD IN THE 21ST CENTURY: TIME TREND ANALYSES

Mortality Trends in Inflammatory Bowel Disease by Age, Sex, and Race in the United States from 1999 to 2020

Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database

P1138 Long-term Epidemiological Trends in Emergency Hospital Admissions and Hospitalizations of Patients with Inflammatory Bowel Diseases in one of the biggest metropolises in western Poland in years 2010 to 2021

Mucosal Healing Among Black and White Patients With Inflammatory Bowel Disease

The national burden of inflammatory bowel disease in the United States from 1990-2019: results from the Global Burden of Disease study database

S991 Increasing Mortality of Inflammatory Bowel Disease in Women: A Population-Based Time-Trend Analysis Using the Global Burden of Diseases Database, 1990-2019

RISING INCIDENCE, MORTALITY, AND DISABILITY-ADJUSTED LIFE YEARS OF INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: A SYSTEMIC ANALYSIS OF THE GLOBAL BURDEN OF DISEASE STUDY

In Patients With Inflammatory Bowel Disease, Racial Disparities Exist in Burden of Vaccine-preventable Disease Hospitalizations and Outcomes

5-Aminosalicylic Acid and Statin Use Are Associated with Reduced Risk of Cancers in Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

DECIPHERING THE BURDEN OF INFLAMMATORY BOWEL DISEASE LANDSCAPE (1990-2019) IN HIGH INCOME NORTH AMERICA: PROJECTIONS, TEMPORAL SHIFTS, AND A GLIMPSE BEYOND TO 2040

Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases

The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies

Trends in Diverticular Disease Hospitalizations and Racial Disparities in Outcomes Across the United States

P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares